N-benzyl-4-(4-(3-(3,4-difluorophenyl)thioureido)phenylthio)picolinamide | 1395063-28-1

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: N-benzyl-4-(4-(3-(3,4-difluorophenyl)thioureido)phenylthio)picolinamide
• 英文别名: N-benzyl-4-[4-[(3,4-difluorophenyl)carbamothioylamino]phenyl]sulfanylpyridine-2-carboxamide
• CAS: 1395063-28-1
• 化学式: C₂₆H₂₀F₂N₄OS₂
• 分子量: 506.6
• InChiKey: PEMXUCAKERFUOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  123
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3,4-二氟苯胺 在 三乙烯二胺 、 三光气 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 22.0h， 生成 N-benzyl-4-(4-(3-(3,4-difluorophenyl)thioureido)phenylthio)picolinamide
  参考文献：
  名称：

  Thiourea and thioether derivatives of sorafenib: synthesis, crystal structure, and antiproliferative activity

  摘要：

  A series of novel sorafenib derivatives containing diaryl thiourea and thioether, 9a-u, was designed and synthesized, and their antiproliferative activities against HCT116 and MDA-MB-231 cell lines were also evaluated and described. Most compounds exhibited potent antiproliferative activity against HCT116 cells with IC50 = 1.8-80.4 mu M. Compounds 9p, 9r, and 9s demonstrated competitive antiproliferative activities to sorafenib, against all two cancer cell lines. The structures of all the newly synthesized compounds were determined by H-1 NMR, C-13 NMR, and HRMS, and compound 9n was characterized by single-crystal X-ray diffraction. Primary structure-activity relationships (SAR) have also been established.

  DOI：

  10.1007/s00044-012-0400-8

文献信息

• Thiourea and thioether derivatives of sorafenib: synthesis, crystal structure, and antiproliferative activity
  作者：Jianwen Yao、Jing Chen、Zuopeng He、Wei Sun、Hao Fang、Wenfang Xu

  DOI：10.1007/s00044-012-0400-8

  日期：2013.8

  A series of novel sorafenib derivatives containing diaryl thiourea and thioether, 9a-u, was designed and synthesized, and their antiproliferative activities against HCT116 and MDA-MB-231 cell lines were also evaluated and described. Most compounds exhibited potent antiproliferative activity against HCT116 cells with IC50 = 1.8-80.4 mu M. Compounds 9p, 9r, and 9s demonstrated competitive antiproliferative activities to sorafenib, against all two cancer cell lines. The structures of all the newly synthesized compounds were determined by H-1 NMR, C-13 NMR, and HRMS, and compound 9n was characterized by single-crystal X-ray diffraction. Primary structure-activity relationships (SAR) have also been established.